Roche to test whether new drug can prevent Alzheimer’s
The new late-stage study will focus on people who are at risk of cognitive decline.
The new late-stage study will focus on people who are at risk of cognitive decline.
New Jersey-based drugmaker Bristol Myers Squibb this month dedicated its first production facility in Indiana, a former north-side warehouse transformed with $160 million into a clean-room manufacturing site for radiopharmaceutical cancer therapies.
The Justice Department argued that a federal judge was wrong to block the National Institutes of Health from making cuts to align with President Donald Trump’s priorities.
The event, a partnership between the tissue bank and the city’s WNBA All-Star 2025 Host Committee, seeks 500 women to donate breast tissue for cancer research.
Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.
Syndeio Biosciences sees burgeoning potential to treat mental health and cognitive conditions, including Alzheimer’s and depression, with therapies that target the almost countless minuscule brain synapses that give people the ability to think and function.
The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other conditions because it comes in pill form, not an injection.
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
The results showed that the number of severe adverse events for patients was 54.3% higher than that of drugs made in emerging economies.
A judge on Monday prevented the National Institutes of Health from changing the percentage that universities and medical schools are paid in facilities and administrative costs in 22 states.
The National Institutes of Health said the change would save more than $4 billion a year, effective immediately.
Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new Indiana University IU Launch Accelerator for Biosciences, or IU LAB.
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human papillomavirus infections before cancer develops and to treat HPV cancers after detection.
Family members, a determined coroner and state researchers are behind a renewed effort to identify all of the unknown dead whose remains are among some 10,000 bones and fragments unearthed on Herbert Baumeister’s suburban Indianapolis property.
Kosali Simon, an Indiana University and Regenstrief Institute researcher, will study the treatment and outcomes of patients with Alzheimer’s and related dementias.
After 10 long years, the company that has developed a collagen biomaterial to help heal tissue is readying itself for its next big steps: regulatory approval and commercial launch.
Sen. Todd Young visited the 16 Tech innovation district Monday to underscore the work of a young federal agency that wants to shake up the conventional model of funding biomedical research.
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And modes of drug delivery are becoming increasingly complex.
The Joint Center of Excellence for Point of Care Precision Medicine aims to develop better personalized care for patients with diabetes, cancer, Alzheimer’s disease and pediatric rare disease.